GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Cyclically Adjusted Revenue per Share

GlycoNex (ROCO:4168) Cyclically Adjusted Revenue per Share : NT$0.09 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GlycoNex's adjusted revenue per share for the three months ended in Mar. 2024 was NT$0.085. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$0.09 for the trailing ten years ended in Mar. 2024.

During the past 12 months, GlycoNex's average Cyclically Adjusted Revenue Growth Rate was -35.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-15), GlycoNex's current stock price is NT$26.55. GlycoNex's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was NT$0.09. GlycoNex's Cyclically Adjusted PS Ratio of today is 295.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlycoNex was 313.33. The lowest was 51.89. And the median was 98.24.


GlycoNex Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for GlycoNex's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex Cyclically Adjusted Revenue per Share Chart

GlycoNex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.43 0.27 0.15 -

GlycoNex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.13 - 0.09

Competitive Comparison of GlycoNex's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, GlycoNex's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoNex's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GlycoNex's Cyclically Adjusted PS Ratio falls into.



GlycoNex Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlycoNex's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.085/131.7762*131.7762
=0.085

Current CPI (Mar. 2024) = 131.7762.

GlycoNex Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.001 100.560 0.001
201409 0.002 100.428 0.003
201412 0.097 99.070 0.129
201503 0.014 99.621 0.019
201506 0.058 100.684 0.076
201509 0.000 100.392 0.000
201512 0.018 99.792 0.024
201603 0.001 100.470 0.001
201606 0.001 101.688 0.001
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.006 102.862 0.008
201706 0.001 103.349 0.001
201709 0.000 104.136 0.000
201712 0.001 104.011 0.001
201803 0.001 105.290 0.001
201806 0.005 106.317 0.006
201809 0.003 106.507 0.004
201812 0.003 105.998 0.004
201903 0.004 107.251 0.005
201906 0.002 108.070 0.002
201909 0.000 108.329 0.000
201912 0.003 108.420 0.004
202003 0.001 108.902 0.001
202006 0.001 108.767 0.001
202009 0.002 109.815 0.002
202012 0.001 109.897 0.001
202103 0.005 111.754 0.006
202106 0.004 114.631 0.005
202109 0.001 115.734 0.001
202112 0.047 117.630 0.053
202203 0.137 121.301 0.149
202206 0.152 125.017 0.160
202209 0.001 125.227 0.001
202212 0.016 125.222 0.017
202303 0.002 127.348 0.002
202306 0.015 128.729 0.015
202309 0.009 129.860 0.009
202312 0.000 129.419 0.000
202403 0.085 131.776 0.085

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


GlycoNex  (ROCO:4168) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GlycoNex's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=26.55/0.09
=295.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlycoNex was 313.33. The lowest was 51.89. And the median was 98.24.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GlycoNex Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of GlycoNex's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoNex (ROCO:4168) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.

GlycoNex (ROCO:4168) Headlines

No Headlines